Replies to post #818108 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

The most likely scenario is that CHM agreed with MHRA in Nov that DCVax was precluded from approval.
That would have triggered an appeal process (which they (NWBO) were entitled to) that could take up to 6 months.
April 28 would be about 6 months. We'll see if I am right in the next week to 6 weeks.
The trial failed and then there was crossover, changed endpoint and then very questionable external controls used.
If what I say is accurate, no regulatory body would ever accept another application from NWBO for ANYTHING - after all this nonsense, game playing and attempts to do and end run around the regulators.
JMHO, good luck to all.

[williamssc]

The key reason for moving from Progression Free Survival (PFS) to Overall Survival (OS) was that Progression Free Survival turned out to be unreliable for measuring tumor progression for this type of immunotherapy treatment in glioblastoma. Overall Survival is considered the most objective endpoint because it simply measures how long a person lives. But your right so far there is no cure but with DCVax-L longer life over SOC.